ATAI Life Sciences closes $149.5 million public offering

ATAI Life Sciences (NASDAQ: ATAI) completed a public offering of 27,283,750 common shares at $5.48 per share, generating approximately $149.5 million in gross proceeds before fees and expenses, according to a company statement.

The offering included the full exercise of underwriters' option to purchase an additional 3,558,750 shares. The underwriters exercised their option on October 17, 2025, with the offering closing on October 20, 2025.

New investors in the financing included Janus Henderson Investors, Foresite Capital, Deep Track Capital, and HBM Partners. Existing investors participating included Ferring Ventures, Columbia Threadneedle Investments, Ally Bridge Group, Woodline Partners LP, and ADAR1 Capital Management.

The clinical-stage biopharmaceutical company plans to use proceeds to advance clinical development of its product pipeline. Specific funding targets include the Phase 3 clinical program for BPL-003 nasal spray through top-line data from the first Phase 3 trial, completing the Phase 2 trial of VLS-01 buccal film, and finishing the Phase 2a study for EMP-01 oral treatment.

The company estimates its cash resources, including proceeds from this offering, will fund operations into 2029 based on current operating plans.

Jefferies LLC served as lead bookrunner, with Berenberg Capital Markets LLC as passive bookrunner. Oppenheimer & Co. Inc. and Canaccord Genuity LLC acted as co-managers, while Lucid Capital Markets provided financial advisory services.

ATAI focuses on developing treatments for mental health disorders using psychedelic-based therapies. The company's pipeline includes three programs in Phase 2 clinical development targeting treatment-resistant depression and social anxiety disorder.

You May Also Be Interested In

• Greenland Mines prices $20M public offering of common stock
• Veea Inc. announces 1-for-20 reverse stock split effective Aug. 28
• Priority Commerce to acquire IntelliPay, targeting public sector